Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.

Idoroenyi AmanamJanny YaoAlfredo PuingNi-Chun TsaiDiana SamuelsDat NgoStephanie HoHaris AliAhmed AribiShukaib ArslanAndrew ArtzMyo HtutPaul B KollerAmandeep SalhotraKaramjeet SandhuLiana NikolaenkoAnna PawlowskaGeoffrey ShouseAnthony SteinGuido MarcucciStephen FormanRyotaro NakamuraSanjeet DadwalMonzr M Al Malki

Published in: Cancer medicine (2023)

This study demonstrates that SARS-CoV-2 specific mAb was safe and may reduce hospitalization compared to what is reported in malignant hematology patients at high risk for disease progression. Our HCT cohort patients had less hospitalization rate compared with HM cohort patients.

Keyphrases

end stage renal disease
sars cov
chronic kidney disease
ejection fraction
prognostic factors
monoclonal antibody
stem cells
peritoneal dialysis
cell proliferation
patient reported outcomes
bone marrow
cell death